If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
284
results.
Updated on
01/09/2026 [06:53:00]
Results 50 to 75 of 284
Absstract of: AU2025228064A1
The present disclosure relates generally to pharmaceutical compositions (e.g., solid oral dosage forms) of the compound of Formula I: Also disclosed are methods of treating or preventing human immunodeficiency virus (HIV) infection in a human, including orally administering to the human the solid oral dosage forms or pharmaceutical compositions disclosed herein.
Absstract of: WO2026174646A1
Provided are a new venom polypeptide-dendrimer complex, and a preparation method therefor and the use thereof. Specifically, provided is a scorpion venom polypeptide, wherein the amino acid sequence of the scorpion venom polypeptide is FLGGLLSSIF. A new scorpion venom polypeptide (designated as C9) is isolated and identified. Moreover, a new polypeptide-polyamidoamine dendrimer complex G5C9 (i.e., nanoparticles) having a glioblastoma (GBM)-targeting effect is constructed. Compared with polypeptide C9, G5C9 exhibits significantly improved cellular uptake efficiency. G5C9 can enter cells via endocytosis and targets lysosomes, and inhibits lysosomal function and mTORC1, thereby promoting nuclear translocation of TFEB and further inducing autophagic cell death. Therefore, G5C9 provides a new targeted anti-GBM approach both in vitro and in vivo.
Absstract of: WO2026174955A1
The present invention belongs to the field of biomedicine. Provided are an organic molecular self-assembly serving as a carrier-free system, and a preparation method therefor and the use thereof. Provided is a self-assembly, which is composed of steroidal molecules, and by means of optimizing the molecular structures of these steroids and critical aggregation concentrations thereof, a carrier-free system formed via self-assembly of the steroidal molecules is prepared. The carrier-free system can be loaded with a drug to prepare a drug nanocomposite. In the nanocomposite, the efficacy of the drug is improved, and the effects of reducing toxicity and improving efficacy can be achieved. If the steroid molecules used are themselves biologically active, the pharmacological activity of the steroid molecules remains unaffected after being prepared into the drug nanocomposite. The carrier-free system has the advantages of both a carrier-free nano-preparation and a nano-preparation using a conventional material as a carrier.
Absstract of: WO2026175548A1
The present invention relates to a polymer system with a nano-in-micro architecture (fucoidan micromatrix with PLGA nanoparticles incorporated therein) and finds application as a system for controlled delivery of low molecular weight water-soluble medicinal substances (e.g. galantamine hydrobromide, benzydamine hydrochloride, betahistine hydrochloride, etc.). The system includes polylactic-coglycolic acid (PLGA) nanoparticles in a fucoidan matrix, with the PLGA content being from 1% to 10% and fucoidan content being from 90% to 99% in the form of a fucoidan matrix with 100% PLGA nanoparticles incorporated therein, with the microparticles having an average diameter of 2 μm to 10 μm. The polymer system for controlled release of low molecular weight water-soluble drugs, when loaded with low molecular weight water soluble drugs such as galantamine, benzydamine, doxylamine, contains polylactic-co-glycolic acid from 1% to 10% and fucoidan from 90% to 99% in the form of a fucoidan matrix with PLGA nanoparticles incorporated therein, in the form of a fucoidan matrix with PLGA nanoparticles incorporated therein from 94% to 99% and a low molecular weight water-soluble drug from 1% to 6%, wherein the microparticles have an average diameter of 2 μm to 10 μm.
Absstract of: WO2026176481A1
The present invention provides lipid-polymer hybrid nanoplexes for delivery of negatively charged biomolecular payloads, and to method of preparing these nanoplexes. The disclosed hybrid delivery system exhibits enhanced cellular uptake, stability, and transfection efficiency.
Absstract of: WO2026176366A1
Disclosed is a process for the assembly modified solid lipid nanoparticles (m-SLNs) by a process that comprises: (i) (a) a therapeutic amount of one or more psychedelics, (b) a solid lipid at room temperature (25 °C) that can be composed of mono-, di, and tri- glycerides, (c) a primary surfactant, (d) optionally, one or more co-surfactant(s), (e) optionally, the addition of a liquid lipid at room temperature (25 °C), (f) optionally, the incorporation of a targeting moiety for a target receptor to initiate a physiological response. For the species to be considered a m-SLN, it must incorporate component (e) and/or component (f). (ii) high-shear mixing said ingredients in a container to form a coarse suspension product, and (iii) subjecting the coarse suspension through a microfluidic device to produce a modified solid lipid nanoparticle containing a psychedelic(s)
Absstract of: WO2026176208A1
Disclosed herein is a versatile injectable nano-bioactive scaffold designed to achieve both immediate soft tissue volumization and long-term tissue regeneration. By utilizing biocompatible polymers such as hyaluronic acid, chitosan, and alginate, along with self-assembling peptides and nano-structured carriers including mesoporous silica nanoparticles and liposomes, the system facilitates controlled release of essential growth factors. This innovative approach delivers sustained bioactivity, significantly reducing the need for repeated injections and minimizing inflammatory complications. The system promises superior clinical outcomes, advancing the field of tissue engineering and regenerative medicine by providing an effective and lasting solution for tissue repair and regeneration.
Absstract of: WO2026178500A1
Among hospital–acquired infections, Pseudomonas aeruginosa-associated urinary tract infections (UTIs) are mainly caused by indwelling urethral catheters (catheter-associated UTIs or CAUTIs) and are difficult to treat, resulting in high rates of morbidity among hospitalized patients. While antibiotics can successfully treat bacteria in the bladder lumen, they are inefficient at crossing stratified urothelium plasma membranes to kill persistent intracellular bacterial communities (IBCs). Herein, UTI IBCs are targeted by locally delivering the antibiotic gentamicin and/or the steroid hormone estradiol via polymeric nanogels conjugated with a cell-penetrating peptide Cys-Gly-Lys-Arg-Lys (CGKRK - SEQ ID NO:1). This approach delivered more intracellular gentamicin compared to drug delivered in solution in vitro and more estradiol compared to conventional methods. In an acute UTI murine model, the nanogel cell-penetrating peptide drug delivery system facilitated the transport of gentamicin into the urothelium and resulted in > 90% clearance of a uropathogenic P. aeruginosa clinical strain in vivo.
Absstract of: WO2026178146A1
Provided herein are nanobodies that specifically bind to PSMA8 and various compositions of such nanobodies. Also provided are method of using the nanobodies in therapeutics and diagnostics for cancer.
Absstract of: WO2026176369A1
Disclosed is a process for the assembly solid lipid nanoparticles by a process that comprises: mixing (i) a therapeutic amount of one or more psychedelic agents, (ii) a protein-based drug carrier using desolvation under high-shear mixing conditions to form a coarse-sized particulate product, and passing the coarse-sized particulate product through a microfluidic device under high shear conditions to produce a protein-based drug nanocarrier containing the one or more psychedelic agents.
Absstract of: US20260250417A1
0000 An engineered nanobody conjugate is provided, comprising: a Variable Heavy domain of Heavy chain (VHH) nanobody; a peptide single transmembrane domain (STMD); and a peptide linker between the nanobody and the STMD. The invention also provides a method of making an immunoliposome composition, comprising: mixing the engineered nanobody according to claim 1 with a liposome composition; and forming 100 nm liposomes from the liposome composition, having between 200 to 2500 chimeric nanobodies per 100 nm liposome. An engineered nanobody conjugate is provided comprising an ordered sequence of a peptide affinity tag, a Variable Heavy domain of Heavy chain (VHH) nanobody, a peptide linker, a cysteine residue, and a peptide fatty acylation signal.
Absstract of: WO2026176372A1
Disclosed is a Pickering emulsion composition and a process for manufacturing Pickering emulsions (PEs) which comprises: (a) combining (i) a therapeutic amount of one or more psychedelics, (ii) a colloidal stabilizing particle, (iii) optionally a co- stabilizing particle) s) or surfactant(s), (iv) an organic vehicle under high-shear mixing conditions to form a coarse emulsion or thin film product, and (b) producing a Pickering emulsion containing the one or more a psychedelic agents by subjecting the coarse emulsion through a microfluidic device or hydrating the thin film product. It would be desirable to have an effective process to make stable, effective, PE compositions that could be used with psychedelics.
Absstract of: US20260248953A1
0000 A method of treating cancer cells to achieve apoptosis including contacting the cancer cells with a porous particulate nanocomposite in an amount sufficient to kill the cancer cells. The porous particulate nanocomposite contains a magnetic nickel ferrite (NiFe<2>O<4>) having an inverse spinel crystal structure; and, monodisperse spherical silica (Sil) particles onto which the magnetic NiFe<2>O<4 >is dispersed. The nanocomposite is functionalized with cis-diammine (cyclobutane-1,1-dicarboxylate-O,O′)platinum(II) (carboplatin or Carbpt) and folic acid (FA). The cancer cells are cells of colon cancer, colorectal cancer and/or cervical cancer.
Absstract of: WO2026178051A1
Compositions and methods for treatment of cancer are disclosed herein. In some embodiments, a composition for treating cancer includes a first dynamic hydrogel having a polymer non-covalently crosslinked with a plurality of nanoparticles and a first immunotherapeutic agent, and a second dynamic hydrogel having a polymer non-covalently crosslinked with a plurality of nanoparticles and a second immunotherapeutic agent, where the first dynamic hydrogel may be configured to be administered within a tumor in a subject to form an intratumoral depot and the second dynamic hydrogel may be configured to be administered to the subject external to the tumor to form a peritumoral depot.
Absstract of: WO2026176368A1
Disclosed is a process for the assembly niosome vesicles by a process that comprises: (a) dissolving: (i) a therapeutic amount of one or more psychedelics, (ii) a primary non-ionic surfactant, (iii) optionally, one or more ionic or non-ionic co- surfactant(s), and (iv) an inhibitor of a metabolic enzyme pertaining to psychedelics in an organic solvent; (b) removing the organic solvent to form a thin-film; (c) hydrating the thin film with an aqueous medium to form coarse sized particles; and (d) processing the coarse sized particles with high-shear conditions and microfluidic processing using a microfluidic production device that will produce a niosome product that contains said one or more psychedelic agents.
Absstract of: WO2026178308A1
Provided herein are methods of preparing a purified composition comprising an antibody-lipid nanoparticle conjugate, in which the antibody addition and conjugation steps are incorporated into the downstream processing stage, resulting in a continuous one-pot process for the production and processing of antibody-lipid nanoparticle conjugates. Also provided herein are antibody-lipid nanoparticle conjugates prepared by such methods. Further provided herein are tangential flow filtration (TFF) apparatuses configured to circulate a composition comprising the lipid nanoparticle during addition of the antibody, and TFF apparatuses comprising an antibody-lipid nanoparticle conjugate.
Absstract of: WO2026178002A1
Immunogenic compositions containing a lipo-oligosaccharide sialyltransferase (LST) protein or antigenic fragment thereof and an adjuvant are provided. Further immunogenic compositions contain a lipid nanoparticle and a nucleic acid encoding LST protein or an antigenic fragment thereof enclosed within the lipid nanoparticle. Vaccine compositions and methods of protecting or treating a subject from a bacterial infection are also provided.
Absstract of: WO2026175419A1
Provided are an anti-CD8 antibody, and a multispecific antibody, fusion protein, conjugate and lipid nanoparticle containing the antibody or an antigen-binding fragment thereof. Further provided are a detection reagent and pharmaceutical composition containing the antibody or the antigen-binding fragment thereof, which can be used for CD8+ cell detection, localization, and/or imaging, and for treating or preventing a disease.
Absstract of: WO2026174384A1
A fusion polypeptide comprises: (1) a malaria-associated antigen-binding moiety and (2) a nanocage monomer or subunit thereof, wherein the malaria-associated antigen-binding moiety comprises an antibody or antigen-binding fragment thereof comprising a heavy chain variable region (VH) comprising a CDR-H1, CDR-H2, and CDR-H3 having sequences which each differ by at most two amino acid residues from the CDR-H1, CDR-H2, and CDR-H3 sequences of a Pfs230 antibody, respectively; and/or a light chain variable region (VL or VK) comprising a CDR-L1, CDR-L2, and CDR-L3 having sequences which each differ by at most two amino acid residues from the CDR-L1, CDR-L2, and CDR-L3 sequences of a Pfs230 antibody, respectively.
Absstract of: US20260248899A1
0000 The disclosure generally relates to Cathepsin S-sensitive linkers, short amino acid sequences attached to antigens that form a structure termed a hybrid peptide. Further disclosed are spherical nucleic acids (SNAs), nanostructures with a core surrounded by a shell of oligonucleotides, wherein in some embodiments the hybrid peptide is attached to one or more oligonucleotides in the shell of oligonucleotides. In some aspects, the disclosure provides a SNA comprising: (a) a nanoparticle core; (b) a shell of oligonucleotides comprising one or more oligonucleotides attached to the nanoparticle core; and (c) a hybrid peptide attached to one or more oligonucleotides in the shell of oligonucleotides, wherein the hybrid peptide comprises a Cathepsin S-sensitive linker and an antigen.
Absstract of: WO2026178127A1
The present invention relates to lipid nanoparticle compositions that include a polypeptide, a cation, a compound capable of coordinating cations, and a plurality of encapsulating lipids, as well as methods of using the lipid nanoparticle compositions in the treatment of disease, and methods for preparing the lipid nanoparticle compositions. The lipid nanoparticle compositions may be used for treating diseases in a subject, such as autoimmune diseases or cancer.
Absstract of: WO2026175979A1
The present invention relates to the field of ionizable lipids and compositions thereof. More particularly, the present invention relates to ionizable lipids or pharmaceutically acceptable salts thereof comprising a moiety, the moiety comprising an ionizable nitrogen attached adjacent to a thioamide group. The present invention further relates to a method for preparing said ionizable lipids, lipid nanoparticles comprising said ionizable lipids, and medical uses thereof (e.g, to deliver biologically active agents, such as nucleic acids, to cells and tissues).
Absstract of: US20260248963A1
0000 The present application provides methods of treating a cancer in subjects who have been subjected to a KRAS inhibitor and/or harbor a KRAS secondary mutation by administering complexes (e.g., genome-editing complexes or complexes having RNAi) or nanoparticles specifically targeting a mutated KRAS. Exemplary genome-editing complexes or nanoparticles comprise cell-penetrating peptides and a guide RNA, and optionally a DNA nuclease (such as Cas9) or a polynucleotide encoding the DNA nuclease.
Absstract of: WO2026178151A1
The present invention relates to lipid nanoparticle compositions that include a polypeptide, a cation, a compound capable of coordinating cations, and a plurality of encapsulating lipids, as well as methods of using the lipid nanoparticle compositions in the treatment of disease, and methods for preparing the lipid nanoparticle compositions. The lipid nanoparticle compositions may be used for treating diseases in a subject, such as autoimmune diseases or cancer.
Nº publicación: WO2026175904A1 27/08/2026
Applicant:
NANOGRAB LTD [GB]
NANOGRAB LIMITED
Absstract of: WO2026175904A1
The present invention relates to a lipid nanoparticle comprising: (a) an ionizable lipid; (b) a helper lipid; (c) a sterol; and (d) a PEGylated lipid, wherein: (i) the PEGylated lipid comprises a hydrocarbon chain comprising more than 14 C atoms; and/or (ii) the PEGylated lipid is at a concentration of at least 3 %mol.
BOPI
Electronic site
